睡前高血压治疗改善心血管风险降低:Hygia Chronotherapy Trial
Hygia Chronotherapy Trial 在初级保健机构中纳入19 084例高血压患者,随机分为睡前服用全部每日剂量或清醒后服用,随访中位6.3年。睡前治疗组主要心血管病结局风险显著低于清醒后治疗组(HR 0.55,95%CI 0.50-0.61,P<0.001)。
要点
- 睡前服用≥1种降压药较清醒后服用显著降低主要心血管病结局风险
- 睡前治疗还改善动态血压控制,包括睡眠血压降幅和血压下降率
- 各单项结局(心血管死亡、心梗、冠脉血运重建、心衰、卒中)均显著降低
核心结论
- 高血压患者常规睡前服用≥1种降压药较清醒后服用可改善动态血压控制并显著减少主要心血管病事件。
研究设计与样本
- 多中心、对照、前瞻性终点试验,纳入19 084例高血压患者(10 614男/8470女,年龄60.5±13.7岁),1:1分配至睡前服药组(n=9552)或清醒后服药组(n=9532)。
- 随访期间至少每年进行48小时动态血压监测,中位随访6.3年。
主要发现
- 主要心血管病结局(心血管死亡、心肌梗死、冠状动脉血运重建、心力衰竭或卒中)共1752例发生。
- 睡前组较清醒后组主要心血管病结局的校正HR为0.55(95%CI 0.50-0.61),P<0.001。
- 心血管死亡HR 0.44(95%CI 0.34-0.56),心肌梗死HR 0.66(95%CI 0.52-0.84),冠状动脉血运重建HR 0.60(95%CI 0.47-0.75),心力衰竭HR 0.58(95%CI 0.49-0.70),卒中HR 0.51(95%CI 0.41-0.63),各单项P<0.001。
- 睡前组显示睡眠血压降幅显著增强及睡眠相对血压下降率增加。
临床怎么用
- 对高血压患者可考虑将≥1种降压药安排在睡前服用,以改善动态血压控制并降低心血管事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The Hygia Chronotherapy Trial, conducted within the clinical primary care setting, was designed to test whether bedtime in comparison to usual upon awakening hypertension therapy exerts better cardiovascular disease (CVD) risk reduction. METHODS AND RESULTS: In this multicentre, controlled, prospective endpoint trial, 19 084 hypertensive patients (10 614 men/8470 women, 60.5 ± 13.7 years of age) were assigned (1:1) to ingest the entire daily dose of ≥1 hypertension medications at bedtime (n = 9552) or all of them upon awakening (n = 9532). At inclusion and at every scheduled clinic visit (at least annually) throughout follow-up, ambulatory blood pressure (ABP) monitoring was performed for 48 h. During the 6.3-year median patient follow-up, 1752 participants experienced the primary CVD outcome (CVD death, myocardial infarction, coronary revascularization, heart failure, or stroke). Patients of the bedtime, compared with the upon-waking, treatment-time regimen showed significantly lower hazard ratio-adjusted for significant influential characteristics of age, sex, type 2 diabetes, chronic kidney disease, smoking, HDL cholesterol, asleep systolic blood pressure (BP) mean, sleep-time relative systolic BP decline, and previous CVD event-of the primary CVD outcome [0.55 (95% CI 0.50-0.61), P < 0.001] and each of its single components (P < 0.001 in all cases), i.e. CVD death [0.44 (0.34-0.56)], myocardial infarction [0.66 (0.52-0.84)], coronary revascularization [0.60 (0.47-0.75)], heart failure [0.58 (0.49-0.70)], and stroke [0.51 (0.41-0.63)]. CONCLUSION: Routine ingestion by hypertensive patients of ≥1 prescribed BP-lowering medications at bedtime, as opposed to upon waking, results in improved ABP control (significantly enhanced decrease in asleep BP and increased sleep-time relative BP decline, i.e. BP dipping) and, most importantly, markedly diminished occurrence of major CVD events. TRIAL REGISTRATION: ClinicalTrials.gov, number NCT00741585.
引用
- Hermida RC, Crespo JJ, Domínguez-Sardiña M, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. 2020. PMID: 31641769. doi:10.1093/eurheartj/ehz754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。